These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17024791)

  • 1. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
    Blondeau JM; Blondeau LD; Hesje C; Borsos S
    J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
    Hesje CK; Borsos SD; Blondeau JM
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
    Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
    Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T; Hori T; Sugimori G; Yamano Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.
    Blondeau JM; Shebelski SD; Hesje CK
    Int J Antimicrob Agents; 2015 Jun; 45(6):594-9. PubMed ID: 25752567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P; Blondeau JM
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
    Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
    Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2010 Aug; 63(4):312-8. PubMed ID: 21298864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
    Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.